A double blinded, Randomised Clinical Study to Assess the Efficacy and Safety of Amrith Noni Artho Plus in Patients with Gout flare. - NI

Valyou Products Private Limited0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年3月4日

试验速览

暂无简介。

•1) Male and female participants aged 18 years and over consulting for current Gout flare.
•2) Participants have been diagnosed for Chronic Gout by a general practitioner and/or orthopedic physician/surgeon with or without joint aspiration, blood tests, imaging or diagnostic criteria
•3) Participants who have no plans to start new treatments during the study period
•4) Patients who require anti-inflammatory treatment, do not use anti-inflammatory/analgesic medications on a regular basis, or are unsatisfied with their treatments and want to alter them.
•5) Patients ready to give written informed consent and willing to comply the study protocol.

•1) Participants with glucose-6-phosphate dehydrogenase deficiency.
•2) Subjects with a history of surgery or gastrointestinal bleed and gastric ulcer.
•3) Participants with RA, OA, septic arthritis, during the past 3 months.
•4) Participants with uncontrolled medical conditions such as angina, hypertension, cardiovascular diseases, impaired liver function, kidney failure, gallbladder disease, malignancies, neurological diseases, or psychiatric conditions.
•5) Participants using other complementary and alternative medicine or any addiction to psychotropic agents and opioids.
•6) Prior or active users of a uricase-containing drugs, anticoagulants, NSAID, naproxen or low-dose colchicine.
•7) Any history of allergy to any of the drugs/investigational products.
•8) Participation in any other clinical trial within 30 days of screening.
•9) Pregnant and lactating women and women of childbearing age who do not follow adequate contraceptive measures

发起方

Valyou Products Private Limited